论文部分内容阅读
病理分期为N_2的ⅢA期非小细胞肺癌(NSCLC)异质性强,生存差异明显。术后放疗在其综合治疗中的地位仍不明确。二维时代的研究显示术后放疗对生存无获益,但随着放疗设备和技术的不断改进,术后辅助放疗在ⅢA(N_2)期NSCLC中的价值需要重新评估。现有大规模的回顾性分析提示采用现代放疗技术和适当的放疗剂量对pN_2患者有生存获益,但目前仍缺乏高级别证据的前瞻性研究。
The pathological stage N 2 Ⅲ A non-small cell lung cancer (NSCLC) heterogeneity, survival significantly different. Postoperative radiotherapy in its comprehensive treatment of the status remains unclear. However, with the continuous improvement of radiotherapy equipment and techniques, the value of postoperative adjuvant radiotherapy in stage Ⅲ A (N_2) NSCLC needs to be re-evaluated. The current large-scale retrospective analysis suggests that the use of modern radiotherapy techniques and the appropriate dose of radiation to survival in patients with pN2 benefit, but there is still a lack of high-level evidence of prospective studies.